Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03696277 · ClinicalTrials.gov registry record · Phase 2
SAbR For Oligo-Progressive Renal Cell Cancer.
A Phase 2 study of Oligoprogressive Renal Cell Carcinoma, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT03696277 is a Phase 2 study of Oligoprogressive Renal Cell Carcinoma that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 21 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03696277, a Phase 2 study of Oligoprogressive Renal Cell Carcinoma, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
Metastatic kidney cancer patients on systemic therapy often develop resistance to limited sites that leads to changing of the systemic therapy. Local therapy to the sites of progression may allow patients to continue on the same systemic therapy that is otherwise effective and being tolerated well. Hypothesis: Stereotactic ablative radiation (SAbR) can delay the change of systemic therapy with oligoprogressive renal cell cancer (RCC) and improve progression free survival (PFS). Primary Objectives: • To evaluate the benefit of SAbR for oligo-progressive mRCC (Metastatic Renal Cell Cancer). Secondary Objectives: • To measure the toxicity, safety and tolerance of concurrent systemic therapy and SAbR for mRCC patients and its impact on quality of life.
Conditions Studied
Interventions
- RADIATION Stereotactic ablative body radiation (SABR)
Study Locations (1)
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2024-01-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03696277
The ClinicalTrials.gov registry entry for NCT03696277 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Oligoprogressive Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Stereotactic ablative body radiation (SABR) is the first listed.
NCT03696277 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03696277 about?
NCT03696277 is a clinical study titled "SAbR For Oligo-Progressive Renal Cell Cancer.". Metastatic kidney cancer patients on systemic therapy often develop resistance to limited sites that leads to changing of the systemic therapy. Local therapy to the sites of progression may allow patients to continue on the same systemic therapy that is otherwise effective and being tolerated well. ...
What is the current status of trial NCT03696277?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2018-10-01. Estimated completion is 2024-01-23.
What conditions does trial NCT03696277 study?
This clinical trial studies the following conditions: Oligoprogressive Renal Cell Carcinoma.
What interventions are being tested in trial NCT03696277?
The interventions under investigation include: Stereotactic ablative body radiation (SABR) (RADIATION).
Who is sponsoring clinical trial NCT03696277?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03696277 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.